Literature DB >> 20180615

Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.

April E Myzienski1, Mark F Lutz, Maureen A Smythe.   

Abstract

Unfractionated heparin infusion therapy is often administered using a weight-based dosing strategy for the treatment of venous thromboembolism. In the last several decades, the prevalence of obesity in the United States has increased significantly. The applicability of weight-based heparin dosing recommendations in the obese and morbidly obese population is uncertain, as limited data are available. We describe a 388-kg man who was started on an intravenous infusion of heparin according to hospital protocol for suspected pulmonary embolism. The patient was given a 5000-unit heparin bolus followed by an initial heparin infusion rate of 1500 units/hour, the maximum initial rate specified in the protocol. After additional infusion rate adjustments, a therapeutic activated partial thromboplastin time (aPTT) was reached 55 hours later with a heparin infusion rate of 3650 units/hour. Due to concerns of heparin-induced thrombocytopenia, heparin therapy was discontinued, and fondaparinux 5 mg/day was started. However, heparin therapy was restarted 4 days later for persistent, refractory hypoxemia and recurrent concerns of possible pulmonary embolism. During this second course, a therapeutic aPTT was achieved with a heparin infusion rate of 3550 units/hour. The patient developed bloody pulmonary secretions (with a therapeutic aPTT), necessitating the discontinuation of the heparin infusion. The patient later died after developing pulseless electrical activity. Standard weight-based heparin dosing protocols that specify maximum doses for initial bolus and infusion rates can result in significant delays in time to achieve therapeutic anticoagulation in the obese and morbidly obese patient. Despite limited data on heparin dosing in obesity, we recommend the use of a dosing weight to determine initial heparin dosing when treating venous thromboembolism in morbidly obese patients. It is reasonable to consider one of the following formulas: dosing weight = ideal body weight (IBW) + 0.3(actual body weight [ABW] - IBW), or dosing weight = IBW + 0.4(ABW - IBW).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180615     DOI: 10.1592/phco.30.3.324

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  5 in total

1.  Treatment of Suspected Pulmonary Embolism in a Super-Obese Individual.

Authors:  Keith Sine
Journal:  Can J Hosp Pharm       Date:  2015 Nov-Dec

Review 2.  Perioperative management of the obese surgical patient.

Authors:  L H Lang; K Parekh; B Y K Tsui; M Maze
Journal:  Br Med Bull       Date:  2017-12-01       Impact factor: 4.291

Review 3.  Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism.

Authors:  Maureen A Smythe; Jennifer Priziola; Paul P Dobesh; Diane Wirth; Adam Cuker; Ann K Wittkowsky
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

4.  Heparin Increases Food Intake through AgRP Neurons.

Authors:  Canjun Zhu; Pingwen Xu; Yanlin He; Yexian Yuan; Tao Wang; Xingcai Cai; Lulu Yu; Liusong Yang; Junguo Wu; Lina Wang; Xiaotong Zhu; Songbo Wang; Ping Gao; Qianyun Xi; Yongliang Zhang; Yong Xu; Qingyan Jiang; Gang Shu
Journal:  Cell Rep       Date:  2017-09-05       Impact factor: 9.423

5.  Clinical and critical care concerns in severely ill obese patient.

Authors:  Sukhminder Jit Singh Bajwa; Vishal Sehgal; Sukhwinder Kaur Bajwa
Journal:  Indian J Endocrinol Metab       Date:  2012-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.